Tikun Europe is a pharmaceutical company that cultivates, processes and merchandises medical cannabis on a 56.000 square meters site, 80km west of Athens, at Corinth. It produces cannabis medicinal products, in accordance to Good Manufacturing Practices. The facility unit deals with the greenhouse cultivation and industrial processing of cannabis flowers for the production of medicinal products. Tikun Olam provides Tikun Europe with the very competitive advantage of one of the most reputable name in the global medical cannabis industry in combination with a specialized know-how and an extensive clinical research. The company is dedicated to improve patients' treatments, wellness and overall quality of life. Furthermore, Tikun Europe exploits an extensive patient treatment database of over 30.000 patients in order to provide and develop the most resulting medical cannabis products.
Our mission is to bring cure and alleviation providing evidence based medical cannabis treatment worldwide.
With more than 10 years of clinical trials and
laboratory studies, Tikun has a successful record of treating ailments like cancer pain, Crohn’s, Parkinson’s, autism, & epilepsy and holds unprecedented patient clinical data collection, with over 30.000 patient records. This extensive research and database provides Tikun Europe the great advantage of access to knowledge and insights that no other competitor has in the medical cannabis industry.
Establishment of Tikun Olam Israel
Co-founder Medreleaf pioneers in the Canadian medical cannabis industry
Established Tikun Olam USA operating in Nevada, Washington, Rhode Island, Maryland, Massachusetts, Illinois and California
Co-founder Medifarm Australia: Queensland's first licensed medicinal cannabis developer
Establishment of Tikun Europe
Production Facility Tikun Europe
Establishment of Tikun Europe Rep. Offices
Tikun is one of the most reputable and trusted brands among the medical cannabis industry. It holds a great track-record of clinical research, know-how and awards for its special production of strains.
The brand Tikun was introduced in the market in 2005 with the establishment of Tikun Israel. Since then, the brand has further been developed with the establishment of MedReleaf in Canada in 2014 which was acquired by Aurora in 2018. Afterwards the establishment of Tikun USA took place in 2016, then Medifarm-Tikun Oceania in 2017, and finally Tikun Europe in 2018, with state-of-the art facilities.
Since the legalization of medical cannabis production and export in Greece, in March 2018, there are several companies willing to take advantage of the market. Medical cannabis use was legalized in Greece in June 2017. Shortly, in March 2018, Greece introduced law 4523/2018 allowing the farming processing of medical cannabis.
If Greece were to benefit from medical cannabis to the same extent as other countries that have introduced medical cannabis, it could inject up to EUR 2 Billion into the economy. Greece has great potential for developing a strong cannabis industry both for medical and industrial applications due to its geomorphology and climate conditions.
Ideal location of the facility since it constitutes the tipping point of connection among West Europe, Greece and Middle East.
Climate conditions are suitable for lower set up and manufacturing costs.
Low labour cost in comparison to the other European countries.
Financial growth and political stability.